Initial Treatment for Prostatomegaly Grade 1

Treatment Algorithm for Grade 1 Prostatomegaly

Alpha blockers should be offered as the first-line treatment option for patients with grade 1 prostatomegaly presenting with bothersome lower urinary tract symptoms (LUTS), providing rapid symptom relief by relaxing smooth muscle in the prostate and bladder neck 1, 2
Alpha blockers improve symptoms by 4-7 points on the International Prostate Symptom Score (IPSS) compared to 2-4 points with placebo 1
Alpha blockers provide relatively quick symptom improvement, usually within 2-4 weeks 3

The choice of alpha blocker should be based on patient age, comorbidities, and potential side effect profiles, with tamsulosin having a lower risk of orthostatic hypotension but higher risk of ejaculatory dysfunction compared to other alpha blockers 2, 4, 5
Doxazosin should be used cautiously in patients with hypertension and cardiac risk factors due to increased risk of congestive heart failure 4, 5

Alpha blockers can cause orthostatic hypotension, dizziness, fatigue, ejaculatory problems, and nasal congestion, with patients planning cataract surgery needing to inform their ophthalmologists about alpha blocker use due to risk of intraoperative floppy iris syndrome (IFIS) 1, 4, 5

5-Alpha Reductase Inhibitors (5-ARIs) are not recommended as first-line monotherapy for grade 1 prostatomegaly, but can be used for patients with demonstrable prostatic enlargement, reducing prostate size by 15-25% after 6 months of treatment and providing modest symptom improvement 1, 2, 4, 5, 6
Tadalafil 5mg daily can be considered, especially in patients with concurrent erectile dysfunction, providing modest symptom improvement but may be less effective than alpha blockers 6, 7

Patients should be evaluated 4-12 weeks after initiating treatment to assess response, with follow-up including IPSS assessment and may include post-void residual (PVR) measurement and uroflowmetry 3

Alpha blockers used for LUTS should not be assumed to adequately control hypertension, with separate management may be required, and 5-ARIs should not be used as first-line therapy for grade 1 prostatomegaly without evidence of significant prostate enlargement 4, 5
5-ARIs reduce PSA by approximately 50%, which should be considered when screening for prostate cancer, and tadalafil should not be combined with alpha blockers as this combination offers no advantage over either agent alone 6, 7